Imipenem Resistance Among <i>Pseudomonas aeruginosa</i> Isolates Risk Factors for Infection and Impact of Resistance on Clinical and Economic Outcomes

Lautenbach, Ebbing; Weiner, Mark G.; Nachamkin, Irving; Bilker, Warren B.; Sheridan, Angela; Fishman, Neil O.

doi:10.1086/507274

Cited by 141 publications

(115 citation statements)

References 23 publications

Supporting

Mentioning

105

Contrasting

Unclassified

Order By: Relevance

“…The drug resistance rates are largely determined by the pattern of antibiotic usage in the hospital setting. Ciprofloxacin use has been reported to be an independent risk factor for development of fluoroquinolone and carbapenem resistance [12][13][14]. Therefore, several interventions aimed at modifying the antibiotic prescription pattern have been tried, to decrease the resistance rates.…”

Section: Discussionmentioning

confidence: 99%

Changing Trend in the Antibiotic Resistance Pattern of Pseudomonas Aeruginosa Isolated from Wound Swabs of Out-Patients and in-Patients of a Tertiary Care Hospital

Joseph

Devi²,

Shashikala³

et al. 2013

JCDR

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Changing Trend in the Antibiotic Resistance Pattern of Pseudomonas Aeruginosa Isolated from Wound Swabs of Out-Patients and in-Patients of a Tertiary Care Hospital

Joseph

Devi²,

Shashikala³

et al. 2013

JCDR

View full text Add to dashboard Cite

“…Resistance of this organism to imipenem increased from 20% to 60% during the study period. Prior fluoroquinolone use has been identified as a risk factor for the emergence of imipenem-resistant P. aeruginosa (IRPA) [12,13]. A decrease in the permeability of the cellular wall in fluoroquinolone-resistant isolates of P. aeruginosa induces cross-resistance to carbapenems [12].…”

Section: Discussionmentioning

confidence: 99%

“…Prior fluoroquinolone use has been identified as a risk factor for the emergence of imipenem-resistant P. aeruginosa (IRPA) [12,13]. A decrease in the permeability of the cellular wall in fluoroquinolone-resistant isolates of P. aeruginosa induces cross-resistance to carbapenems [12]. Out of 30 IRPA, 21 (70%) showed resistance to ciprofloxacin or levofloxacin, suggesting that crossresistance developed for imipenem due to prior use of fluoroquinolones (p < 0.05).…”

Section: Discussionmentioning

confidence: 99%

Drug resistance patterns of bacteria isolated from patients with nosocomial pneumonia at Tehran hospitals during 2009-2011

Haeili

Ghodousi

Nomanpour

et al. 2013

J Infect Dev Ctries

View full text Add to dashboard Cite

Introduction: Nosocomial pneumonia remains an important cause of mortality and morbidity worldwide. Surveillance programs play an important role in the identification of common etiologic agents and local patterns of antimicrobial resistance. Methodology: In this study we determined the frequency and antimicrobial susceptibility of pathogens isolated from patients with nosocomial pneumonia during 2009 to 2011. Results: A total of 642 bacteria were isolated from 516 suspected samples. Acinetobacter baumannii (21.1%, n = 136), was the commonest isolated pathogen followed by Pseudomonas aeruginosa (17.4%, n = 112), Staphylococcus aureus (15.8%, n = 102) and enterococci (8.4% n = 54). The most effective therapeutic agents against A. baumannii were polymyxin B (95.5% susceptible), ceftriaxone/tazobactam (72% susceptible) and levofloxacin (52.9% susceptible). Polymixin B (89.2% susceptible), ceftriaxone/tazobactam (89.2% susceptible) and piperacillin-tazobactam (80.3% susceptible) were found to be the most active agents against P. aeruginosa. Extended-spectrum betalactamases were detected among isolates of K. pneumoniae (45.4%) and E. coli (20.3%). Overall, the prevalence of methicillin-resistant S. aureus and vancomycin resistant enterococci were 80.4% and 40.7% respectively. Linezolid was found to be the most active antibiotic against these pathogens. The etiology of 50% of the nosocomial infection cases was polymicrobial. Conclusions: The combination of ceftriaxone/tazobactam seems to be beneficial agent against multidrug-resistant Gram-negative bacilli isolated form respiratory tract infections. The results of our study can be used for guiding appropriate empiric therapy in this geographic region.

show abstract

“…Resistant infections not only re-suit in increased morbidity and mortality but also dramatically increase healthcare costs. 24 " 28 It is ironic that in the twenty-first century we are encountering bacterial infections for which we have no treatment. A multifaceted approach is necessary to prevent, detect, and control the emergence of antimicrobial-resistant organisms.…”

Section: Infect Control Hosp Epidemiol 2012;33(4):322-327mentioning

confidence: 99%

Policy Statement on Antimicrobial Stewardship by the Society for Healthcare Epidemiology of America (SHEA), the Infectious Diseases Society of America (IDSA), and the Pediatric Infectious Diseases Society (PIDS)

Fishman¹

2012

Infect. Control Hosp. Epidemiol.

587

249

View full text Add to dashboard Cite

Antimicrobial resistance has emerged as a significant healthcare quality and patient safety issue in the twenty-first century that, combined with a rapidly dwindling antimicrobial armamentarium, has resulted in a critical threat to the public health of the United States. Antimicrobial stewardship programs optimize antimicrobial use to achieve the best clinical outcomes while minimizing adverse events and limiting selective pressures that drive the emergence of resistance and may also reduce excessive costs attributable to suboptimal antimicrobial use. Therefore, antimicrobial stewardship must be a fiduciary responsibility for all healthcare institutions across the continuum of care. This position statement of the Society for Healthcare Epidemiology of America, the Infectious Diseases Society of America, and the Pediatric Infectious Diseases Society of America outlines recommendations for the mandatory implementation of antimicrobial stewardship throughout health care, suggests process and outcome measures to monitor these interventions, and addresses deficiencies in education and research in this field as well as the lack of accurate data on antimicrobial use in the United States.

show abstract

Imipenem Resistance Among Pseudomonas aeruginosa Isolates Risk Factors for Infection and Impact of Resistance on Clinical and Economic Outcomes

Cited by 141 publications

References 23 publications

Changing Trend in the Antibiotic Resistance Pattern of Pseudomonas Aeruginosa Isolated from Wound Swabs of Out-Patients and in-Patients of a Tertiary Care Hospital

Changing Trend in the Antibiotic Resistance Pattern of Pseudomonas Aeruginosa Isolated from Wound Swabs of Out-Patients and in-Patients of a Tertiary Care Hospital

Drug resistance patterns of bacteria isolated from patients with nosocomial pneumonia at Tehran hospitals during 2009-2011

Policy Statement on Antimicrobial Stewardship by the Society for Healthcare Epidemiology of America (SHEA), the Infectious Diseases Society of America (IDSA), and the Pediatric Infectious Diseases Society (PIDS)

Contact Info

Product

Resources

About